Palivizumab
Based on 3 publication(s) in Google Scholar
Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.63%
- No. CAS: 188039-54-5
- Peso molecular:145.5 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Palivizumab
More
Actividad biológica
Human IgG1 kappa
Virus
RSV-F
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:The cotton rat model of RSV infection[1].
-
Dosage:0.625-5 mg/kg (i.m.) or 0.312-10 mg/kg (i.v.)
-
Administration:Intramuscular injection (i.m.) or intravenous injection (i.v.); single dose
-
Result:Reduced virus replication and did not cause RSV infection or pathological increase in both initial and secondary attacks.
-
Animal Model:BALB/c mice[2].
-
Dosage:0.05 mg/kg
-
Administration:Intranasally administered; single dose
-
Result:Reduced the RSV load.
-
Animal Model:Capsaicin-induced neurogenic inflammation in the airways of rats[3].
-
Dosage:15 mg/kg
-
Administration:Subcutaneous injection (s.c.); single dose
-
Result:Reduced neurogenic extravasation and neurogenic inflammation.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
A0A0X8XRK2
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized Human respiratory syncytial virus (RSV) Prefusion glycoprotein F can bind Palivizumab. The EC50 for this effect is 2.043 ng/mL.
Chemical Information
-
No. CAS 188039-54-5
-
Appearance Liquid
-
Peso molecular 145.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Palivizumab]
-
Synonyms
MEDI 493
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Int Immunopharmacol
An oral vaccine based on the Ad5 vector with a double-stranded RNA adjuvant protects mice against respiratory syncytial virus. [Abstract]2025 Jan 27:146:113970. PMID: 39736241 -
Bioconjug Chem
Resin-Supported Site-Specific Antibody Conjugation Method Leads to Antibody-Drug Conjugates with Retained Efficacy and Improved Stability. [Abstract]2025 Aug 21. PMID: 40839643 -
Npj Viruses
STAT1 signaling controls cholesterol metabolism in epithelial cells and RSV-induced syncytia formation. [Abstract]2026 Feb 16;4(1):10. PMID: 41699197
Pureza y Documentación
-
Ficha de datos (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Johnson S, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997 Nov;176(5):1215-24. [Content Brief]
[2]. Jacobino SR, et al. Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. MAbs. 2018 Apr;10(3):453-462. [Content Brief]
[3]. Piedimonte G, et al. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. Pediatr Res. 2000 Mar;47(3):351-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Palivizumab Related Classifications
HY-P9944 Related Classifications
Powered by Bioz